| Kevin L Klein, CRNA | |
|
900 E Broadway Ave, Bismarck, ND 58501-4520 | |
| (701) 530-7000 | |
| Not Available |
| Full Name | Kevin L Klein |
|---|---|
| Gender | Male |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 24 Years |
| Location | 900 E Broadway Ave, Bismarck, North Dakota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1639222110 | NPI | - | NPPES |
| 1453016 | Medicaid | ND |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | R26283 (North Dakota) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| 701 Anesthesia Associates Pllc | 2769818491 | 6 |
News Archive
KIKA Clinical Solutions announced that Sara Gambrill, Senior Editor of CenterWatch, will be a keynote speaker at KIKA's U.S. User Group Meeting. KIKA is the leading provider of advanced EDC solutions for clinical trials, and creators of the Veracity Web-based platform for Clinical Asset Management. The User Group Meeting will take place October 21 and 22 in Boston.
The debate over whether routine circumcision of baby boys being either hygienic, safe or brutal and medically unnecessary continues in San Francisco. This November, residents will vote if the procedure shall be continued.
As Rep. Paul Ryan, R-Wis., moves to the national stage as GOP presidential hopeful Mitt Romney's running mate pick, his proposals to reshape Medicare, Medicaid and other safety net programs emerge as political lightning rods.
Takeda Pharmaceutical Company Limited (Takeda) announced today that Takeda Global Research & Development Center, Inc., U.S., submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for azilsartan medoxomil (development code: TAK-491), an angiotensin II receptor blocker (ARB) under investigation for the treatment of hypertension. Discovered by Takeda, azilsartan medoxomil is designed to lower blood pressure by blocking the action of a vasopressor hormone, angiotensin II.
› Verified 5 days ago
| Entity Name | St Alexius Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205868429 PECOS PAC ID: 8426960865 Enrollment ID: O20031104000146 |
News Archive
KIKA Clinical Solutions announced that Sara Gambrill, Senior Editor of CenterWatch, will be a keynote speaker at KIKA's U.S. User Group Meeting. KIKA is the leading provider of advanced EDC solutions for clinical trials, and creators of the Veracity Web-based platform for Clinical Asset Management. The User Group Meeting will take place October 21 and 22 in Boston.
The debate over whether routine circumcision of baby boys being either hygienic, safe or brutal and medically unnecessary continues in San Francisco. This November, residents will vote if the procedure shall be continued.
As Rep. Paul Ryan, R-Wis., moves to the national stage as GOP presidential hopeful Mitt Romney's running mate pick, his proposals to reshape Medicare, Medicaid and other safety net programs emerge as political lightning rods.
Takeda Pharmaceutical Company Limited (Takeda) announced today that Takeda Global Research & Development Center, Inc., U.S., submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for azilsartan medoxomil (development code: TAK-491), an angiotensin II receptor blocker (ARB) under investigation for the treatment of hypertension. Discovered by Takeda, azilsartan medoxomil is designed to lower blood pressure by blocking the action of a vasopressor hormone, angiotensin II.
› Verified 5 days ago
| Entity Name | Bismarck Surgical Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487814356 PECOS PAC ID: 6800855099 Enrollment ID: O20041004001040 |
News Archive
KIKA Clinical Solutions announced that Sara Gambrill, Senior Editor of CenterWatch, will be a keynote speaker at KIKA's U.S. User Group Meeting. KIKA is the leading provider of advanced EDC solutions for clinical trials, and creators of the Veracity Web-based platform for Clinical Asset Management. The User Group Meeting will take place October 21 and 22 in Boston.
The debate over whether routine circumcision of baby boys being either hygienic, safe or brutal and medically unnecessary continues in San Francisco. This November, residents will vote if the procedure shall be continued.
As Rep. Paul Ryan, R-Wis., moves to the national stage as GOP presidential hopeful Mitt Romney's running mate pick, his proposals to reshape Medicare, Medicaid and other safety net programs emerge as political lightning rods.
Takeda Pharmaceutical Company Limited (Takeda) announced today that Takeda Global Research & Development Center, Inc., U.S., submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for azilsartan medoxomil (development code: TAK-491), an angiotensin II receptor blocker (ARB) under investigation for the treatment of hypertension. Discovered by Takeda, azilsartan medoxomil is designed to lower blood pressure by blocking the action of a vasopressor hormone, angiotensin II.
› Verified 5 days ago
| Entity Name | 701 Anesthesia Associates Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447897897 PECOS PAC ID: 2769818491 Enrollment ID: O20200128003217 |
News Archive
KIKA Clinical Solutions announced that Sara Gambrill, Senior Editor of CenterWatch, will be a keynote speaker at KIKA's U.S. User Group Meeting. KIKA is the leading provider of advanced EDC solutions for clinical trials, and creators of the Veracity Web-based platform for Clinical Asset Management. The User Group Meeting will take place October 21 and 22 in Boston.
The debate over whether routine circumcision of baby boys being either hygienic, safe or brutal and medically unnecessary continues in San Francisco. This November, residents will vote if the procedure shall be continued.
As Rep. Paul Ryan, R-Wis., moves to the national stage as GOP presidential hopeful Mitt Romney's running mate pick, his proposals to reshape Medicare, Medicaid and other safety net programs emerge as political lightning rods.
Takeda Pharmaceutical Company Limited (Takeda) announced today that Takeda Global Research & Development Center, Inc., U.S., submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for azilsartan medoxomil (development code: TAK-491), an angiotensin II receptor blocker (ARB) under investigation for the treatment of hypertension. Discovered by Takeda, azilsartan medoxomil is designed to lower blood pressure by blocking the action of a vasopressor hormone, angiotensin II.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kevin L Klein, CRNA Po Box 997, Bismarck, ND 58502-0997 Ph: (701) 530-7000 | Kevin L Klein, CRNA 900 E Broadway Ave, Bismarck, ND 58501-4520 Ph: (701) 530-7000 |
News Archive
KIKA Clinical Solutions announced that Sara Gambrill, Senior Editor of CenterWatch, will be a keynote speaker at KIKA's U.S. User Group Meeting. KIKA is the leading provider of advanced EDC solutions for clinical trials, and creators of the Veracity Web-based platform for Clinical Asset Management. The User Group Meeting will take place October 21 and 22 in Boston.
The debate over whether routine circumcision of baby boys being either hygienic, safe or brutal and medically unnecessary continues in San Francisco. This November, residents will vote if the procedure shall be continued.
As Rep. Paul Ryan, R-Wis., moves to the national stage as GOP presidential hopeful Mitt Romney's running mate pick, his proposals to reshape Medicare, Medicaid and other safety net programs emerge as political lightning rods.
Takeda Pharmaceutical Company Limited (Takeda) announced today that Takeda Global Research & Development Center, Inc., U.S., submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for azilsartan medoxomil (development code: TAK-491), an angiotensin II receptor blocker (ARB) under investigation for the treatment of hypertension. Discovered by Takeda, azilsartan medoxomil is designed to lower blood pressure by blocking the action of a vasopressor hormone, angiotensin II.
› Verified 5 days ago
Rodney N Kraft, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 300 N 7th St, Bismarck, ND 58501 Phone: 701-323-6000 Fax: 701-323-5709 | |
Renee Christ, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 900 E Broadway Avenue, Bismarck, ND 58501 Phone: 701-530-7000 | |
Jamie L Hawk, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 222 N 7th St, Bismarck, ND 58501 Phone: 701-323-6000 Fax: 701-323-5709 | |
Kim E Geiger, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 900 E Broadway Avenue, Bismarck, ND 58501 Phone: 701-530-7000 Fax: 701-530-8842 | |
Rebekah Charchenko, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 900 E Broadway Ave, Bismarck, ND 58501 Phone: 701-530-7000 | |
Brendin Michael Steiner, DNP Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 335 Willow Ln, Bismarck, ND 58504 Phone: 701-590-2762 | |
Donald Christopher Martin, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 900 E Broadway Ave, Bismarck, ND 58501 Phone: 701-530-7000 |